Alvotech is currently the only company dual listed on stock exchanges in Iceland and the US.
As stated in Alvotech’s announcement, the company is focused solely on the development and manufacture of biosimilar medicines for patients which can reduce the cost of health services worldwide. Biosimilars are therapeutic equivalents to biologics. The announcement goes on to state that Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the US, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. The company has about 800 employees.
Landsbankinn Corporate Finance has been Alvotech’s certified advisor in the preparation and execution of listing on the Nasdaq First North Iceland Growth Market. We thank Alvotech for successful and enjoyable collaboration.
